Introduction {#S1}
============

Gaucher disease (GD), first described in 1882 by Dr. Phillipe Gaucher, is an inborn error of metabolism due to mutations in the gene *GBA1*, encoding the lysosomal enzyme glucocerebrosidase (GCase) ([@B55]). GCase, a lysosomal hydrolase, cleaves both glucosylceramide (GlcCer) to ceramide and glucose, and glucosylsphingosine (GlcSph) into sphingosine and glucose. This rare autosomal recessive inherited disorder occurs in approximately 1:40,000--60,000 live births in the general population, whereas among Ashkenazi Jews the frequency increases to around 1:850 ([@B19]). In patients with GD, "Gaucher cells," macrophages engorged with lysosomal GlcCer, present in the spleen, liver, and bone marrow, lead to organomegaly and inflammation ([@B45]; [@B8]; [@B55]). Clinically, there are three types of GD. Type 1 or non-neuronopathic GD presents with organomegaly, bone manifestations, anemia, and thrombocytopenia ([@B45]; [@B8]). Acute neuronopathic GD2, the rarest form with devastating and progressive neurodegeneration including bulbar findings, seizures, and opisthotonos, results in death during infancy or early childhood ([@B8]; [@B54]; [@B69]). Chronic neuronopathic GD3 is characterized by a slower progression of neurological symptoms, with a later onset. These patients have extensive visceral and skeletal involvement, but also may exhibit myoclonic epilepsy, ataxia, impaired eye movements, developmental delay, or intellectual deterioration ([@B54], [@B55]; [@B17]; [@B57]). There is considerable phenotypic variation within each type of GD, including rare patients who develop Parkinson disease (PD).

Parkinson disease, first described in 1817 by James Parkinson, is found in 2--3% of individuals over age 65 ([@B48]). This disease is characterized by the loss of dopaminergic (DA) neurons in the substantia nigra, as well as by Lewy bodies containing alpha-synuclein (α-Syn) ([@B60]; [@B64]), which ultimately result in the classically associated symptoms, tremor, postural instability, bradykinesia, and rigidity ([@B48]). Currently, mutations in *GBA1* are one of the most common genetic risk factors for PD, as well as dementia with Lewy bodies (DLB). Mutations in *GBA1* were found in 5--20% of sporadic PD cases with an estimated odds ratio of 5.4. In DLB the odds ratio was 8.3 ([@B58]; [@B43]; [@B40]). Patients with *GBA1-*associated PD (*GBA1*-PD) resemble those with sporadic PD but exhibit an earlier disease onset. The lysosome, the central player uniting GD and PD, is the main organelle responsible for α-Syn degradation ([@B50]). While the mechanism underlying the association between GD and PD still remains controversial, one hypothesis proposed posits that elevated substrate levels resulting from diminished GCase could stabilize soluble oligomeric α-Syn intermediates, enhancing oligomerization and accumulation of α-Syn within lysosomes ([@B71]; [@B65]). Increased levels of α-Syn in DA neurons could also inhibit the translocation of GCase from the endoplasmic reticulum (ER) to lysosomes which could lead to a gradual increase of the lipid substrates within the lysosome ([@B32]). This positive feedback loop with the combination of inhibited GCase trafficking and α-Syn accumulation may result in neurodegeneration ([@B5]; [@B61]). Furthermore, even patients with PD without *GBA1* mutations have lower levels of GCase, suggesting that in idiopathic PD, reduced GCase activity may also contribute to disease progression ([@B15]; [@B42]).

Due to this apparent reciprocal association between GCase and α-Syn, attention is being directed toward designing therapeutics for GD with implications for PD. Currently, patients with type 1 GD are commonly treated with enzyme replacement therapy (ERT) ([@B20]) which alleviates the hematological, visceral, and sometimes skeletal manifestations, but does not cross the blood-brain-barrier, and thus does not impact neurological involvement or PD manifestations ([@B68]). Substrate reduction therapy (SRT), a second approach for treating GD, focuses on upstream targets, ultimately inhibiting the accumulation of GlcCer ([@B30]). Two SRT drugs approved by FDA have shown efficacy in type 1 GD ([@B53]; [@B7]) and some cross the blood-brain-barrier. However, the current SRTs have not been efficacious for neuronopathic GD (nGD) ([@B7]; [@B39]; [@B73]) and there are several pharmacokinetic limitations ([@B18]).

Pharmacological chaperones, small molecules designed to bind to a specific target protein and assist in the folding of the protein, are also being developed as an alternative treatment approach for GD or GD-associated PD. They further function by stabilizing the enzyme to prevent misfolding and to enhance accurate translocation of the protein from the ER to the Golgi and lysosome ([@B11]; [@B25]). Since most mutations encountered in GD or *GBA1*-PD are missense mutations leading to misfolded enzyme, pharmacological chaperones which cross the blood-brain-barrier provide an attractive therapeutic strategy. Here we review studies of chaperones as a treatment for GD and *GBA1*-PD, focusing on preclinical developments.

Iminosugars {#S2}
===========

The first chaperone considered for GCase was an iminosugar, *N*-(*n*-nonyl) deoxynojirimycin (NN-DNJ). [@B52] reported that the addition of NN-DNJ to fibroblast culture medium increased the activity of GCase in N370S mutant and wild-type but not L444P mutant cells. However, NN-DNJ also inhibits α-glucosidase and GlcCer synthase, rendering it difficult to use as a target-specific drug. Another iminosugar, α-1-C-Nonyl-DIX that specifically inhibits GCase, but not α-glucosidase, doubled the residual cellular activity of GCase in N370S/N370S fibroblasts ([@B11]). Bicyclic nojirimycin (NJ) analogs with a sp2-iminosugar structure were found to be stronger chaperones as well as selective and competitive inhibitors of lysosomal GCase ([@B28], [@B27]; [@B67]). Some of the new sp2-iminosugar derivatives inhibited enzyme activity by 10-fold at pH 5 ([@B35]).

Another type of iminosugar, isofagomine (IFG), was reported to bind to the GCase active site, increase GCase activity in cell lysates and restore lysosomal trafficking of GCase in N370S cells ([@B25]). Incubation of GD patient-derived lymphoblastoid or fibroblast lines with IFG increased GCase activity 3.5- and 1.3-fold and reduced endogenous GlcCer levels ([@B22]). Testing the effects of IFG on GCase activity in a complex nGD mouse model, 4L;C^∗^ (V394L/V394L + saposin C−/−) showed that IFG administration extended lifespan and increased GCase activity and protein levels in the brain and visceral tissue, with attenuation of proinflammatory responses ([@B63]). Further, *in vivo* tests of IFG in homozygous V394L, D409H, and D409V mice, which are nGD models demonstrated increased GCase activity in visceral tissues and brain extracts ([@B62]). Whether the effect of IFG on wild-type GCase could be beneficial in synucleinopathies was evaluated using mice overexpressing human wild-type α-Syn (Thy1- α-Syn). Treating with IFG (AT2101) orally for 4 months improved motor function, diminished microglial inflammatory response in the substantia nigra, reduced α-Syn immunoreactivity in nigral DA neurons, and reduced small α-Syn aggregates ([@B49]). Another study in 4L;C^∗^ mice reported that IFG did not alter the GlcCer and GlcSph accumulation, but attenuated disease progression and altered global expression profiles of brain mRNA and miRNAs ([@B12]). Treating *Drosophila* manipulated to express human wild-type, N370S and L444P *GBA1*, with IFG resulted in decreased ER stress and preserved motor function, suggesting that IFG might have potential as a PD therapy ([@B51]).

De La Mata et al. reported that a distinct iminosugar, NAdBT-AIJ restored mitochondrial dysfunction and GCase activity in L444P mice in combination with coenzyme Q10 ([@B13]). Another pyrrolidine-based iminosugar, α-1-C-tridecyl-DAB (5j) was shown to function as a chaperone inhibitor of GCase enhancing enzyme activity at concentrations 10 times lower than IFG ([@B21]).

Ambroxol {#S3}
========

Ambroxol (ABX), a drug used to treat airway mucus hypersecretion and hyaline membrane disease in newborns, was found to be a pH-dependent, mixed-type inhibitor of GCase, and thus a potential therapy for GD. With its inhibitory activity maximal at neutral pH, ABX is found in the ER, and is undetectable at the acidic pH of lysosomes ([@B31]). GCase activity was enhanced in ABX-treated GD fibroblasts and lymphoblasts. Furthermore, modeling studies indicated that ABX interacts with both active site and non-active site residues of GCase ([@B31]). The tolerability and efficacy of ABX was evaluated in 12 patients with type 1 GD not receiving ERT. While only three patients who continued on ABX for a year had improved platelet counts and decreased organ volumes, the others remained stable, supporting the need for a larger clinical trial ([@B72]). The chaperone activity and cytotoxicity of ABX was tested *in vitro*, demonstrating low cytotoxicity and significantly increased GCase activity in GD and GD+PD fibroblasts with different GD mutations, without any serious adverse effects ([@B6]; [@B29]; [@B34]). Another study in *GBA1*-mutant fibroblasts showed that ABX enhanced GCase activity by increasing Sap C and LIMP-2 protein levels ([@B4]). Testing *in vivo* efficacy of 12 days of ABX in wild-type, L444P carrier and transgenic mice overexpressing human α-Syn demonstrated increased brain GCase activity and decreased total and phosphorylated α-Syn levels ([@B36]). In nonhuman primates, daily administration of ABX increased brain GCase activity, supporting clinical testing in humans ([@B37]). In *Drosophila melanogaster* with a mutated *GBA1b* ortholog, treatment with ABX did not rescue GCase activity, but did ameliorate the unfolded protein response, inflammation and neuroinflammation, and enhance the life span ([@B10]). Several pilot clinical studies of ABX were performed in patients with nGD ([@B44]; [@B47]; [@B23]). One study in five patients with GD3 showed that high-dose oral ABX had good safety and tolerability, significantly increased lymphocyte GCase activity, permeated the blood--brain barrier, and decreased GlcSph levels in the cerebrospinal fluid. The investigators reported that myoclonus, seizures, and pupillary light reflex dysfunction improved, leading to the recovery of gross motor function in two patients ([@B44]). Another study of the long-term safety and efficacy of combined high-dose ABX up to 21 mg/kg/day) and ERT in GD3 showed that during the first 2 years seizure frequency and neurocognitive function worsened, but after the ABX dosage was increased to 27 mg/kg/day, seizure frequency markedly decreased from the baseline, neurocognitive function improved and the drug was tolerated without severe adverse events ([@B23]). However, these are primarily antidotal reports, and a double-blind placebo-control study is needed. ABX is currently being tested under a single-center phase II clinical trial in 75 subjects with mild to moderate PD by randomizing participants into ABX high-dose (1,050 mg/day), low-dose (525 mg/day), or placebo group ([@B59]), and reasonable cerebrospinal fluid levels were attained ([@B41]).

Non-Inhibitory Chaperones {#S4}
=========================

A major limitation of inhibitory chaperones is that the chaperone activity must be balanced against the functional inhibition of GCase. In contrast, non-inhibitory chaperones can assist in the folding of mutant GCase in the ER and the translocation to lysosomes without interfering with the active site of the enzyme, and thus can restore enzyme activity in the lysosome. Several non-inhibitory compounds were identified by a high throughput screening (HTS) assay using an extract of spleen from a patient with GD as the source of mutant enzyme ([@B16]). In this screen, saposin C and other potential cofactors were present in the extract, likely enhancing the detection of non-inhibitory chaperones. The activities of the compounds were confirmed in subsequent cell-based assays using patient-derived fibroblasts. The screen yielded novel pyrazolopyrimidine-based non-inhibitory pharmacological chaperones ([@B46]). [@B3] assessed the efficacy of one non-inhibitory chaperone identified by HTS as a drug candidate for GD or *GBA1*-PD. Since fibroblasts do not store GlcCer, monocyte-derived macrophages from 20 patients with GD and GD iPSC-differentiated macrophages were examined. The non-inhibitory chaperone, NCGC758, enhanced GCase activity, reduced glycolipid storage, and normalized chemotaxis and the production of reactive oxygen species in the macrophages. NCGC758 also reversed inflammatory defects in GD macrophages by inducing autophagy and reducing IL-1b secretion ([@B2]). Another lead non-inhibitory small molecule, NCGC607, was tested in dopaminergic (DA) neurons differentiated from type 1 and 2 GD and GD+PD iPSCs ([@B1]). NCGC607 restored GCase activity and protein levels, and reduced glycolipid storage in GD DA neurons, indicating its therapeutic potential for GD. In addition, NCGC607 reduced α-Syn levels in DA neurons from patients with parkinsonism, suggesting that NCGC607 or a derivative of this lead compound may have efficacy as a treatment for PD ([@B1]). NCGC758 also reduced α-Syn levels and improved lysosomal function in iPSC-derived DA neurons differentiated from patients with GD and PD ([@B33]).

Other Small Molecules {#S5}
=====================

Histone deacetylase inhibitors (HDACi) have also been explored for the treatment of GD by modulating a GCase-associated ubiquitin--proteasome pathway ([@B26]). It was shown that a known HDACi (SAHA) and a unique small-molecule HDACi (LB-205) rescued GCase levels and increased enzymatic activity in fibroblasts derived from patients with GD1 and GD2. It was further shown that HDACi inhibits the deacetylation of heat shock protein (HSP90), resulting in impaired recognition of the mutant peptide by HSP90, thus protecting GCase from degradation ([@B70]).

Recently, S-181, a new small-molecule capable of stabilizing wild-type GCase was developed. S-181 increased GCase activity in iPSC-derived DA neurons from patients with idiopathic PD, as well as in patients with PD carrying *GBA1* mutation c.84dupG and mutations in other PD genes ([@B9]). S-181 treatment in these DA neurons reversed pathogenic phenotypes including the reduced accumulation of oxidized dopamine. It was also shown in [Table 1](#T1){ref-type="table"} that treating wild-type and heterozygous D409V mice with S-181 increased GCase activity in both, resulting in reduction of the lipid substrates and α-Syn in brain ([@B9]).

###### 

Small molecules considered as therapeutics for GD and *GBA1*-associated PD.

  **Name of small molecules**     **Disease modeled**           ***GBA1* mutations tested**            **Model organisms**            **Effect of small molecules**                                                                           **References**
  ------------------------------- ----------------------------- -------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------- ----------------
  **Inhibitory chaperones**                                                                                                                                                                                                                   
  NN-DNJ                          GD1                           N370S                                  Fibroblasts                    Increased GCase activity                                                                                [@B52]
  α-1-C-Nonyl-DIX                 GD1                           N370S                                  Fibroblasts                    Increased GCase activity                                                                                [@B11]
  sp2-iminosugar                  GD1                           F213I, N370S                           Fibroblasts                    Increased GCase activity                                                                                [@B28]
                                  nGD                           L444P, G202R                           DA neurons from iPSCs          Increased GCase activity and protein level                                                              [@B67]
  Isofagomine                     GD1                           N370S                                  Fibroblasts                    Increased GCase activity                                                                                [@B25]
                                  nGD                           L444P                                  Fibroblasts and lymphoblasts   Increased GCase activity Reduced GlcCer levels                                                          [@B22]
                                  nGD                           L444P                                  Mouse                          Increased GCase activity in relevant tissues                                                            [@B22]
                                  nGD                           V394L/V394L + saposin C−/−             Mouse                          Extended lifespan Increased GCase activity and protein levels Attenuation of proinflammatory response   [@B63]
                                  nGD                           V394L, D409H, and D409V                Mouse                          Increased GCase activity in relevant tissues                                                            [@B62]
                                  PD                            α-Syn overexpression                   Mouse                          Improved motor function Reduced α-Syn immunoreactivity Reduced α-Syn aggregates                         [@B49]
                                  nGD                           V394L/V394L + saposin C−/−             Mouse                          Extended lifespan Attenuation of proinflammatory response Altered expression of DEGs\*                  [@B12]
                                  *GBA1*-PD                     N370S, L444P                           Drosophila                     Decreased ER\*\* stress Restored motor function                                                         [@B51]
  NAdBT-AIJ + coQ                 nGD                           L444P                                  Mouse                          Restored mitochondrial dysfunction Increased GCase activity                                             [@B13]
  α-1-C-tridecyl-DAB              GD1                           N370S                                  Fibroblasts                    Increased GCase activity                                                                                [@B21]
  Ambroxol                        GD1                           N370S, F213I                           Fibroblasts and lymphoblasts   Increased GCase activity and protein levels Reduced GlcCer levels                                       [@B31]
                                  GD1,2&3                       N370S, F213I, N188S, G193W, R120W      Fibroblasts                    Increased GCase activity                                                                                [@B29]
                                  GD1,2&3                       N370S, V394L, R120W, R415R, R131C      Fibroblasts                    Increased GCase activity                                                                                [@B6]
                                  GD1 and *GBA1*-PD             N370S, etc.                            Fibroblasts                    Increased GCase activity and protein levels increase GCase mRNA and TFEB mRNA                           [@B34]
                                  *GBA1*-PD and non-*GBA1*-PD   N370S, L444P                           Fibroblasts, drosophila        Increased GCase activity Increased Sap C                                                                [@B4]
                                  PD                            L444P, α-Syn overexpression            Mouse                          Increased GCase activity in brains Reduced α-Syn levels                                                 [@B36]
                                  PD                            wildtype                               Non-human primate              Increased GCase activity in brains                                                                      [@B37]
                                  nGD                           C-terrminal 133aa deletion in *GBAb*   Drosophila                     Reduced unfolded protein response Reduced neuroinflammation Enhanced lifespan                           [@B10]
  **Non-inhibitory Chaperonea**                                                                                                                                                                                                               
  NCGC758                         GD1 GD2                       N370S, L444P, c.84dupG, IVS2+1         Macrophages from iPSCs         Increased GCase activity Reduced GlcCer levels Recovered ROS\*\*\* production Improved chemotaxis       [@B3]
  NCGC758                         GD1                           N370S                                  Macrophages from iPSCs         Induced autophagy and Reduced IL-1β secretion                                                           [@B1]
  NCGC758                         nGD                           N370S, c.84dupG                        DA neurons from iPSCs          Increased GCase activity Reduced α-Syn levels Improved lysosomal function                               [@B33]
  NCGC607                         GD, GD with parkinsonism      N370S, c.84dupG, IVS2+1, L444P         DA neurons from iPSCs          Increased GCase activity Reduced GlcCer and GlcSph levels Reduced α-Syn levels                          [@B1]
  **Others**                                                                                                                                                                                                                                  
  LB-250                          GD                            N370S, L444P                           Fibroblasts                    Inhibit histone deacetylase activity Increased GCase activity and protein levels                        [@B26]
  S-181                           *GBA1*-PD and non-*GBA1*-PD   c.84dupG, wildtype                     DA neurons from iPSCs          Increased GCase activity Reduced GlcCer levels Reduced the oxidized dopamine and α-Syn                  [@B9]
  S-181                           *GBA1*-PD                     D409V                                  Mouse                          Reduced GlcCer and GlcSph levels in brain Reduced α-Syn levels in brain                                 [@B9]

\*Differentially expressed brain mRNAs. \*\*Endoplasmic reticulum. \*\*\*Reactive oxygen species.

Discussion {#S6}
==========

There are several FDA-approved ERT (Cerezyme, etc.) and SRT (Zaversca, etc.) drugs to treat GD. However, ERT does not have utility for *GBA1*-PD since it does not cross the blood-brain- barrier and since substrate accumulation in *GBA1*-PD is minimal, it is unlikely that SRT will be efficacious ([@B56]). Small molecule pharmacological chaperones have been developed to overcome these limitations. The first iminosugar developed, NN-DNJ, increased GCase activity in cells from patients with GD ([@B52]) by strong binding to GCase ([@B66]). However, NN-DNJ only increases enzymatic activity in lines with specific *GBA1* mutations ([@B52]; [@B66]) and also inhibits GlcCer synthase activity in a dose-dependent manner ([@B11]). Isofagomine (IFG) appears to have more target-specific inhibition and broader pre-clinical efficacy in both *in vitro* and *in vivo* models of different types of GD and PD. However, like other inhibitory small molecule chaperones, IFG also causes dosage-dependent inhibition of GCase, limiting its clinical utility. A phase II clinical trial of IFG failed to improve clinical symptoms in patients with GD, likely due to dosing challenges. Ambroxol (ABX) has been evaluated as an inhibitory chaperone with fewer side effects and better efficacy, because its inhibitory effect does not occur at the low pH present in lysosomes. A recent comparative molecular docking analysis showed that ABX has more broad binding affinity toward GCase than NN-DNJ and other SRT drugs ([@B66]). A phase II clinical study of ABX for PD is currently underway ([@B59]).

Non-inhibitory chaperones are highly attractive candidate drugs for the treatment of GD or *GBA1*-PD because they avoid the primary problem associated with inhibitory chaperones, the inhibitory competition with substrates of GCase in the lysosome. A few non-inhibitory chaperones identified by HTS were shown to have disease-reversing effects in cellular models of GD or *GBA1*-PD ([@B3], [@B1]). However, there are also difficulties in developing non-inhibitory chaperones. The binding of non-inhibitory chaperones to sites other than the active site makes it difficult to perform structure-guided optimization of drug efficacy and challenging to evaluate the potential activity of candidate molecules from HTS. To resolve this problem, visualizing the activity of endogenous levels of GCase in live cells is required. This might be achieved through the development of a fluorescence-based substrate probe representing GCase activity in lysosomes of live cells ([@B20]).

To increase the likelihood of success in clinical trials, a properly designed pre-clinical drug testing strategy is essential. Thus, appropriate *in vitro* and *in vivo* disease models which mimic key features of the disease are cessary. DA neurons differentiated from patient iPSCs accumulate α-Syn and oxidized dopamine, and thus can be used to test the efficacy of small molecules for PD ([@B1]; [@B9]). However, mouse models accurately replicating PD phenotypes are still needed. A previous study showed that mice carrying the L444P mutation had increased stability of over-expressed human wild-type and A53T mutant α-Syn ([@B14]). However, the L444P mice did not demonstrate accumulation of α-Syn and there was no PD phenotypes in the L444P carrier mice ([@B38]). While heterozygous L444P mice overexpressing mutant α-Syn had exacerbated motor deficits ([@B14]) and enhanced dopaminergic neurodegeneration ([@B38]), it is not clear whether this phenotype can be used to establish drug efficacy, especially as in patients, the α-Syn levels are not as high, and the protein is not mutated. To identify and optimize candidate non-inhibitory chaperones, new methods for evaluating GCase activity in live cells and more appropriate *GBA1*-PD animal models need to be developed. Three dimensional *in-vitro* cell culture systems can be also considered for drug screening and preclinical validation of candidate drugs, because they more closely resembles the *in-vivo* cell environment than routine *in-vitro* cell culture ([@B24]).
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